|
|
|
|
|
|
|
Highlights from the 2024 AUA Southeastern Section Annual Meeting |
|
|
|
|
| Management of Complications Following RPLND
|
| Charles Peyton, MD
|
| Charles Peyton delivered a State-of-the-Art Lecture at the 2024 SES AUA meeting, focusing on managing complications following RPLND for testicular cancer. He presented a case study illustrating the challenges in treating a patient with a metastatic germ cell tumor and discussed treatment options, including chemotherapy and surgical salvage.
|
|
|
|
|
|
| Darolutamide, Enzalutamide, and Apalutamide for Non-Metastatic Castration-Resistance Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
|
| Zachary Klaassen, MD, MSc
|
| The DEAR study presented at the 2024 AUA Southeastern Section annual meeting compared real-world outcomes of darolutamide, enzalutamide, and apalutamide in nmCRPC patients in the United States. Findings indicated that darolutamide demonstrated lower rates of treatment discontinuation and progression to metastatic disease compared to enzalutamide and apalutamide, along with a lower incidence of adverse events.
|
|
|
|
|
|
| Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities |
| Marc Bjurlin, DO, MSc, FACOS |
| Marc Bjurlin presented on the integration of molecular imaging into urologic oncology clinical practice at the 2024 SES AUA meeting. He discussed the current approaches and future opportunities in molecular imaging for prostate cancer, bladder cancer, and testicular cancer. Dr. Bjurlin highlighted the use of various radiopharmaceuticals, such as PSMA PET in prostate cancer, FDG PET in bladder cancer, and FDG PET in testicular cancer, emphasizing their impact on patient care and diagnostic accuracy. |
|
|
|
|
|
| Darolutamide in Combination with ADT and Docetaxel: Efficacy and Safety by Disease Volume and Risk in the Phase 3 ARASENS Trial
|
| Evan Goldfischer, MD, MBA, FACS
|
| Evan Goldfischer presents findings from the phase 3 ARASENS trial, focusing on the efficacy and safety of darolutamide in combination with ADT and docetaxel-based on disease volume and risk in mHSPC. Regardless of high- or low-volume disease or high- or low-risk status, darolutamide significantly improved overall survival compared to placebo.
|
|
|
|
|
|
|
|
|
|
|
| Addressing Racial Disparities in Prostate Cancer Prediction Models: External Validation and Comparison of Four Models of Pathological Outcome Prediction Before Radical Prostatectomy |
| Mahdi Mottaghi, MD |
| Mahdi Mottaghi presented findings addressing racial disparities in prostate cancer prediction models, particularly focusing on external validation and comparison of four models of pathological outcome prediction before radical prostatectomy. The MUSIC model demonstrated higher net benefit, especially in predicting lymph node invasion outcomes among Black men, highlighting its potential utility in addressing racial disparities in prostate cancer prediction. |
|
|
|
|
|
| Screening with PSA and MRI: Yearly Trends by PI-RADS and Race Shows Stable Diagnosis of NCCN Very Low-Risk Disease |
| Christine Lightfoot |
| Christine Lightfoot presented findings at the 2024 SES AUA meeting regarding screening with PSA and MRI, focusing on yearly trends by PI-RADS and race. The study aimed to evaluate trends in newly diagnosed prostate cancer based on AUA and NCCN risk categories after screening with PSA and MRI at an equal access institution. |
|
|
|
|
|
| Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial |
| Daniel J. George, MD |
| Daniel George presented findings at the 2024 SES AUA meeting regarding the association of PSA response and overall survival in patients with mHSPC in the phase 3 ARASENS trial. The results showed that more patients receiving darolutamide achieved undetectable PSA levels compared to placebo, and they also had a significant delay in time to PSA progression. |
|
|
|
|
|
|
|
|
|
|
|
